Evidence map›Paper›PMID 37199050›Full record

ArticleCancer medicine2023

Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.

Yuki Shimizu, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Yuki ShimizuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.ORCID 0000-0002-3994-5541
Daisuke KajiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Otoya WatanabeDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Kyosuke YamaguchiDepartment of Hematology, Toranomon Hospital, Kajigaya, Japan.
Kosei KageyamaDepartment of Hematology, Toranomon Hospital, Kajigaya, Japan.
Yuki TayaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Kazuya IshiwataDepartment of Hematology, Toranomon Hospital, Kajigaya, Japan.
Shinsuke TakagiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Hisashi YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Yuki-Asano MoriDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Atsushi WakeDepartment of Hematology, Toranomon Hospital, Kajigaya, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Toranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies.

methodHerein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, bendamustine, and cytarabine (R-BAC) at Toranomon Hospital between November 2016 and February 2022.

resultAlthough one patient discontinued R-BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high-dose chemotherapy and autologous stem cell transplantation, and maintained complete remission with a median follow-up of 15 months. Hematological adverse events (AEs) occurred in all patients; however, none developed documented infection. There were also no fatal non-hematological AEs specific to R-BAC.

conclusionR-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Mantle-CellAdultAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideCyclophosphamideCytarabineDoxorubicinHumansPrednisoneRetrospective StudiesRituximabTransplantation, AutologousVincristineBendamustine HydrochlorideCyclophosphamideCytarabineDoxorubicinPrednisoneRituximabVincristineeffective and safeinduction therapymantle cell lymphomarituximab/bendamustine/cytarabinetransplant eligibility

Identifiers

PMID37199050
PMCPMC10278520
OpenAlexW4377010767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.